Outputs (2)

Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway (2016)
Journal Article
Mo, D., Fang, H., Niu, K., Liu, J., Wu, M., Li, S., Zhu, T., Aleskandarany, M. A., Arora, A., Lobo, D. N., Madhusudan, S., Balajee, A. S., Chi, Z., & Zhao, Y. (2016). Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway. Cancer Research, 76(10), https://doi.org/10.1158/0008-5472.CAN-15-2361

Elevation of the DNA-unwinding helicase RECQL4, which participates in various DNA repair pathways, has been suggested to contribute to the pathogenicity of various human cancers, including gastric cancer. In this study, we addressed the prognostic an... Read More about Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway.

3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors (2016)
Journal Article
Onion, D., Argent, R. H., Reece-Smith, A. M., Craze, M. L., Pineda, R. G., Clarke, P. A., Ratan, H. L., Parsons, S. L., Lobo, D. N., Duffy, J. P., Atherton, J. C., McKenzie, A. J., Kumari, R., King, P., Hall, B. M., & Grabowska, A. M. (2016). 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors. Molecular Cancer Therapeutics, 15(4), https://doi.org/10.1158/1535-7163.MCT-15-0598

There is a growing recognition that current preclinical models do not reflect the tumor microenvironment in cellular, biological, and biophysical content and this may have a profound effect on drug efficacy testing, especially in the era of molecular... Read More about 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors.